Biological Evaluation of Arylsemicarbazone Derivatives as Potential Anticancer Agents - Laboratoire de Biologie Intégrative des Modèles Marins
Article Dans Une Revue Pharmaceuticals Année : 2019

Biological Evaluation of Arylsemicarbazone Derivatives as Potential Anticancer Agents

Résumé

Fourteen arylsemicarbazone derivatives were synthesized and evaluated in order to find agents with potential anticancer activity. Cytotoxic screening was performed against K562, HL-60, MOLT-4, HEp-2, NCI-H292, HT-29 and MCF-7 tumor cell lines. Compounds 3c and 4a were active against the tested cancer cell lines, being more cytotoxic for the HL-60 cell line with IC 50 values of 13.08 µM and 11.38 µM, respectively. Regarding the protein kinase inhibition assay, 3c inhibited seven different kinases and 4a strongly inhibited the CK1δ/ε kinase. The studied kinases are involved in several cellular functions such as proliferation, migration, cell death and cell cycle progression. Additional analysis by flow cytometry revealed that 3c and 4a caused depolarization of the mitochondrial membrane, suggesting apoptosis mediated by the intrinsic pathway. Compound 3c induced arrest in G1 phase of the cell cycle on HL-60 cells, and in the annexin V assay approximately 50% of cells were in apoptosis at the highest concentration tested (26 µM). Compound 4a inhibited cell cycle by accumulation of abnormal postmitotic cells at G1 phase and induced DNA fragmentation at the highest concentration (22 µM).
Fichier principal
Vignette du fichier
pharmaceuticals-12-00169-v2.pdf (7.2 Mo) Télécharger le fichier
document.html (7.2 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03864455 , version 1 (21-11-2022)
hal-03864455 , version 2 (24-09-2024)

Identifiants

Citer

Anne Cecília Nascimento da Cruz, Dalci José Brondani, Temístocles Ítalo de Santana, Lucas Oliveira da Silva, Elizabeth Fernanda da Oliveira Borba, et al.. Biological Evaluation of Arylsemicarbazone Derivatives as Potential Anticancer Agents. Pharmaceuticals, 2019, 12 (4), pp.169. ⟨10.3390/ph12040169⟩. ⟨hal-03864455v2⟩
196 Consultations
33 Téléchargements

Altmetric

Partager

More